Earnings season is in full swing in the pharma sector with major players sharing their latest results. On Tuesday (February 4 ...

Media conglomerate Disney (DIS) beat on top and bottom line numbers for the first quarter and provided a forecast for the ...

Meta shares moved higher Tuesday after setting a record close yesterday, as investors bid up the stock in the aftermath of a solid quarterly earnings report and optimism about the company's AI-related ...

Toymaker Mattel on Tuesday forecast full-year profit above Wall Street expectations after beating holiday quarter estimates, ...

The S&P 500 will trade in a range that implies the index dropping as much as 8% or rising a little over 1% in the coming ...

AI (artificial intelligence) darling Palantir Technologies (PLTR) stock earned a price target lift from Wedbush analyst Daniel Ives. The ...

Wednesday's chart of the day from Raymond James's Larry Adam has caught our eye. According to Adam, excluding Tesla Inc., ...

In what may be an important signal of economic confidence, more Americans now expect stock prices to increase than at any ...

It comes as the health secretary called on experts and survivors to share their experiences to help shape the new National ...

CORE EARNINGS PER SHARE: Core earnings per share are expected to rise to $2.07 from $1.45 the year prior, according to the same consensus. AstraZeneca's stock is up 7.9% since the start of 2024.

Pfizer also reaffirmed its full-year 2025 guidance, which includes revenue in a range of $61 billion to $64 billion and adjusted earnings between $2.80 and $3 a share. Analysts surveyed by FactSet are ...

Pfizer’s PFE 2024 revenue reached $63.6 billion, near the high end of its $61 billion-$64 billion guidance range. Management ...